693 related articles for article (PubMed ID: 24799481)
21. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.
Wu X; Pertovaara H; Korkola P; Vornanen M; Järvenpää R; Dastidar P; Eskola H; Kellokumpu-Lehtinen PL
Acta Oncol; 2014 Aug; 53(8):1093-9. PubMed ID: 24960581
[TBL] [Abstract][Full Text] [Related]
22. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
[TBL] [Abstract][Full Text] [Related]
23. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.
Safar V; Dupuis J; Itti E; Jardin F; Fruchart C; Bardet S; Véra P; Copie-Bergman C; Rahmouni A; Tilly H; Meignan M; Haioun C
J Clin Oncol; 2012 Jan; 30(2):184-90. PubMed ID: 22162590
[TBL] [Abstract][Full Text] [Related]
24. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
25. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
[TBL] [Abstract][Full Text] [Related]
26. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.
Broccoli A; Casadei B; Stefoni V; Pellegrini C; Quirini F; Tonialini L; Morigi A; Marangon M; Argnani L; Zinzani PL
BMC Cancer; 2017 Apr; 17(1):276. PubMed ID: 28415982
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
28. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
29. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
Chihara D; Oki Y; Ine S; Kato H; Onoda H; Taji H; Kagami Y; Yamamoto K; Morishima Y
Eur J Haematol; 2010 Jun; 84(6):493-8. PubMed ID: 20148943
[TBL] [Abstract][Full Text] [Related]
30. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
Filippi AR; Piva C; Giunta F; Bellò M; Chiappella A; Caracciolo D; Zotta M; Douroukas A; Ragona R; Vitolo U; Bisi G; Ricardi U
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):311-6. PubMed ID: 23916170
[TBL] [Abstract][Full Text] [Related]
31. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
32. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
33. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care.
Vassilakopoulos TP; Pangalis GA; Katsigiannis A; Papageorgiou SG; Constantinou N; Terpos E; Zorbala A; Vrakidou E; Repoussis P; Poziopoulos C; Galani Z; Dimopoulou MN; Kokoris SI; Sachanas S; Kalpadakis C; Dimitriadou EM; Siakantaris MP; Kyrtsonis MC; Dervenoulas J; Dimopoulos MA; Meletis J; Roussou P; Panayiotidis P; Beris P; Angelopoulou MK
Oncologist; 2012; 17(2):239-49. PubMed ID: 22282906
[TBL] [Abstract][Full Text] [Related]
34. Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group.
Cavalli F; Ceriani L; Zucca E
Am Soc Clin Oncol Educ Book; 2016; 35():e368-75. PubMed ID: 27249743
[TBL] [Abstract][Full Text] [Related]
35. The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.
Ishii Y; Tomita N; Tateishi U; Ishiyama Y; Yamamoto E; Hattori Y; Hagihara M; Yamazaki E; Ishigatsubo Y
Med Oncol; 2014 Mar; 31(3):880. PubMed ID: 24504845
[TBL] [Abstract][Full Text] [Related]
36. Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
Dorth JA; Prosnitz LR; Broadwater G; Diehl LF; Beaven AW; Coleman RE; Kelsey CR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):762-7. PubMed ID: 22420972
[TBL] [Abstract][Full Text] [Related]
37. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
[TBL] [Abstract][Full Text] [Related]
38. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.
Goldschmidt N; Kleinstern G; Orevi M; Paltiel O; Ben-Yehuda D; Gural A; Libster D; Lavie D; Gatt ME
Cancer Chemother Pharmacol; 2016 May; 77(5):1053-60. PubMed ID: 27056383
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
